Glucose-lowering therapy after myocardial infarction: More questions than answers

European Heart Journal

Volumn 29, Issue 2, 2008, Pages 141-143

  Radke, Peter W ^a   Schunkert, Heribert ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CANNABINOID 1 RECEPTOR ANTAGONIST; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; EDITORIAL; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; STROKE;

DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

EID: 38349161442     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehm595     Document Type: Editorial

References (14)

1. Malmberg K, Rydén L, Hamsten A, Herlitz J, Waldenström A, Wedel H,Wood DA. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Eur Heart J 1996;17:1337-1344.
2. Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, Hildebrandt P, MacLeod K, Laakso M, Torp-Pedersen C, Waldenström A; DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26:650-661.
3. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L, for the DAGAMI 2 investigators. The impact of glucose-lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction. A report from the DIGAMI 2 trial. Eur Heart J 2008;29:166-176. First published on December 21, 2007, doi:10.1093/eurheartj/ehm518.
4. Anselmino M, Öhrvik J, Malmberg K, Stabdl E, Ryden L, on behalf of the Euro Heart survey investigators. Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus. A report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J 2008;29:177-184. First published on December 21, 2007, doi:10.1093/eurheartj/ehm519.
5. Malmberg K, Rydén L, Hamsten A, Herlitz J, Waldenström A, Wedel H. Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. Cardiovasc Res 1997;34:248-253.
6. Kjekshus J. Treating the diabetic patient with coronary disease. Eur Heart J 1996;17:1298-301.
7. Van den Berghe G. Insulin vs. strict blood glucose control to achieve a survival benefit after AMI? Eur Heart J 2005;26:639-641.
8. Singh S, LokeYK, FurbergCD. Long-termriskof cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-1195.
9. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular disease. Eur Heart J 2007;28:88-136.
10. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial). A randomized controlled trial. Lancet 2007;370:829-840.
11. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.
12. Laakso M, Kuusisto J. Epidemiological evidence for the association of hyperglycaemia and atherosclerotic vascular disease in noninsulin-dependent diabetes mellitus. Ann Med 1996;28:415-418.
13. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
14. Pratley RE, Hardison R, Tilton L et al. Effects of diabetes medications on fibrinolytic activity: the BARI 2D trial. Presented at American Diabetes Association Scientific Sessions 2007; abstract 636-P.